ClinicalTrials.gg
RecruitingNCT04699305Updated Jul 29, 2025

Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers

An observational study in Cutaneous Wounds, sponsored by RedDress Ltd.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by RedDress Ltd. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Feb 2019; still recruiting 7 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Multicenter observational study to explore the efficacy of ActiGraft in the treatment of exuding cutaneous wounds in real-life usage.

02

Conditions studied

  • Cutaneous Wounds

Browse trials for

Keywords

  • DFU, PU, Surgical, Vascular, Trauma
03

In context

Wounds and Injuries

2,221 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.

This study's planned enrollment of 500 is above the median of 169 across 690 observational studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

RedDress Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with all types of exuding cutaneous wound

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥18 years of age
  • Subject has an exuding cutaneous wound
  • Subject agrees to the use of his health data, including photos of his wound in analysis and publications
  • Subject/LAR must be able to read and understand English and/or Spanish

Exclusion criteria

Exclusion Criteria:

  • Subject/LAR is unable to read and understand English or Spanish.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • ActiGraft

    Whole blood clot (WBC) gel

    Device: ActiGraft

Interventions

  • DeviceActiGraft

    Whole blood clot (WBC) gel

06

What researchers measure

Primary outcomes

  1. Percentage area reduction (PAR) at 4 weeks

    Change from baseline at 4 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).

    Time frame: 4 weeks

  2. Nature, frequency, and severity of adverse events in the intent to treat population

    Nature, frequency, and severity (by CTCAE5) of adverse events

    Time frame: 1 year

Secondary outcomes

  1. Percentage area reduction at 8 and 12 weeks

    Change from baseline at 8 and 12 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).

    Time frame: 12 weeks

Other outcomes

  1. Reduction in pain at 4 weeks

    Pain reduction at 4 weeks for wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT) for patients reporting any level of wound related pain (\>1 on a VAS scale of 0-10 points) at baseline

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Wound Care Experts
    Las Vegas, Nevada 89128, United States
    Recruiting
    • Naz Wahab, M.D · Contact
08

References and documents

Publications

  • Williams M, Davidson D, Wahab N, Hawkins J, Wachuku CD, Snyder R. Innovative treatment utilizing an autologous blood clot for diabetic foot ulcers. Wounds. 2022 Jul;34(7):195-200. doi: 10.25270/wnds/21089. PubMed 35881826 ↗

Individual participant data

Plan to share: Yes — The results will be part of several scientific publications

Supporting information: Study protocol

Time frame: Upon publication

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Jul 2026, 88 months after the start.

Of 47 industry-sponsored observational studies under Wounds and Injuries, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 63. This study's planned 88 months is above that.

Counting every sponsor, half of 312 studies reached it within 28 months; a quarter within 12 and three quarters within 60.

Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2021
First posted
Jan 7, 2021
StartActual
Feb 14, 2019
Primary completionEst.
Jul 1, 2026
CompletionEst.
Jan 31, 2027
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04699305
Lead sponsor
RedDress Ltd.
Responsible party
Sponsor
First posted
Jan 7, 2021
Start date
Feb 14, 2019
Primary completion
Jul 1, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jul 29, 2025

Study contacts

Sharon Sirota
Contact
sharon@reddress.co.il
+972545800765
Sharon Sirota
study director · RedDress Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion